Chargement en cours...
A preliminary results of integrated chemotherapy with EGFR receptor tyrosine kinase inhibitors in patients with non-small-cell-lung cancer harboring EGFR mutation
In the open prospective non-randomized single-center study we recruited patients with advanced NSCLC harboring EGFR mutations. Initially there were two months of treatment by gefitinib 250 mg daily. Then, after a 2-week drug-free period, 3 cycles of paclitaxel 175 mg / m2 and carboplatin AUC5 were a...
Enregistré dans:
| Auteurs principaux: | , , , , , , , |
|---|---|
| Format: | Artigo |
| Langue: | Russo |
| Publié: |
Remedium Group LLC
2019-06-01
|
| Collection: | Медицинский совет |
| Sujets: | |
| Accès en ligne: | https://www.med-sovet.pro/jour/article/view/3060 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|